FDA Adverse Event Reports on Compounded GLP-1s: 2025 vs 2026 Comparison

The FDA Adverse Event Reporting System (FAERS) is the most comprehensive database of drug safety signals in the U.S. Here's what the compounded GLP-1 data actually shows — and what it doesn't.

Media coverage of compounded GLP-1 safety typically follows a simple formula: report the scariest-sounding adverse events, imply they're representative, and skip the statistical context. The actual FAERS data tells a more nuanced story.

FAERS (the FDA Adverse Event Reporting System) is a voluntary reporting database where patients, providers, and manufacturers can report suspected adverse events associated with medications. It is the primary signal detection system for post-market drug safety in the United States. But understanding what FAERS data means — and what it doesn't — requires knowing how the system works.

How FAERS Works (And Its Limitations)

With that framework in mind, here's what the compounded GLP-1 FAERS data shows.

The Trend: Report Volumes Are Increasing

FAERS reports mentioning compounded semaglutide and compounded tirzepatide have increased steadily since 2023. This increase correlates directly with the increase in patients using compounded GLP-1 products — more patients using a medication means more adverse event reports, even if the per-patient safety profile hasn't changed.

This is the single most important statistical point in the entire dataset: report volume without a denominator tells you nothing about safety rates. If 500,000 people use compounded semaglutide and 5,000 file reports, that's a 1% reporting rate. If 5 million use it and 50,000 file reports, that's the same 1% rate — but the absolute number looks 10x scarier.

Most Reported Events: Largely Expected

The most commonly reported adverse events in compounded GLP-1 FAERS data mirror the known side-effect profile of brand-name semaglutide and tirzepatide. Nausea, vomiting, diarrhea, constipation, and injection site reactions dominate — the same GI effects reported in the STEP and SURMOUNT clinical trials at similar proportional rates.

This is actually somewhat reassuring. If compounded products had fundamentally different safety profiles from brand-name equivalents (due to potency variation, contamination, or formulation differences), you'd expect to see a different pattern of adverse events — not the same GI-dominant profile. The consistency suggests that compounded semaglutide, when properly formulated, behaves pharmacologically like brand-name semaglutide.

The Serious Events: Context Matters

A smaller but more concerning subset of reports involves serious adverse events: pancreatitis, gallbladder events (cholecystitis, cholelithiasis), thyroid abnormalities, and — in the most alarming reports — hospitalizations and deaths.

Pancreatitis

Pancreatitis is a known class-wide risk for all GLP-1 receptor agonists, including FDA-approved versions. The STEP and SURMOUNT trials documented small but measurable pancreatitis rates in both treatment and placebo groups. FAERS reports of pancreatitis in compounded GLP-1 users are consistent with the class risk — not an additional risk specific to compounding.

Gallbladder events

Rapid weight loss from any cause increases gallstone risk. This is a function of the weight loss itself, not the medication's mechanism. GLP-1 medications that produce more weight loss produce more gallbladder events — compounded or brand-name.

Deaths

Reports of deaths in FAERS mentioning compounded GLP-1 products have generated significant media attention. The critical missing context: FAERS death reports do not establish causation. Many patients using GLP-1 medications have obesity, type 2 diabetes, cardiovascular disease, and other conditions with independent mortality risk. A patient who has a heart attack while taking compounded semaglutide may have the event reported in FAERS — even if the heart attack was caused by underlying cardiovascular disease, not the medication.

What Compounded-Specific Risks Exist

While the overall adverse event profile mirrors brand-name products, there are compounded-specific risk factors that patients should be aware of:

Potency variation. The FDA's own testing found potency ranging from 42% to 170% of labeled concentration in compounded semaglutide samples. Under-potency means reduced efficacy. Over-potency means higher-than-intended dosing, which amplifies side effects and risks. This is the strongest data-backed argument for choosing providers with third-party potency testing.

Sterility concerns. Compounded injectable medications require sterile preparation. Pharmacies not following USP 797 standards for sterile compounding create contamination risk. 503B outsourcing facilities (FDA-registered, cGMP-compliant) have stricter sterility requirements than 503A pharmacies.

Dosing errors. Multi-dose vials require patients to calculate and draw their own doses — a process that's error-prone, especially for patients unfamiliar with syringes. Brand-name auto-injector pens eliminate this risk entirely.

How to Minimize Your Risk

Verify pharmacy credentials. 503B outsourcing facilities have FDA registration and cGMP requirements. Ask your provider specifically whether their pharmacy partner is 503A or 503B.

Ask about potency testing. Third-party certificate of analysis (COA) for each batch is the gold standard. If your provider can't tell you whether their pharmacy tests potency, that's a red flag.

Double-check your dose math. Use the formula: Volume (mL) = Prescribed dose (mg) ÷ Vial concentration (mg/mL). If you're unsure, call your provider before injecting.

Report adverse events. If you experience an unexpected or serious side effect, report it to the FDA's MedWatch system. This data matters — it's how safety signals are detected and how the market gets safer for everyone.

Providers With Strong Safety Track Records